People Lost Up to 85 Pounds on Lilly’s Experimental Weight Loss Drug, Company Says

Eli Lilly’s experimental weight loss drug, retatrutide, has produced impressive results from a late-stage clinical trial. The medication, administered as a weekly injection, helped participants lose an average of 28% of their body weight – around 70 pounds – with nearly half losing 30% or more.

The phase 3 trial’s findings are comparable to those achieved through bariatric surgery, which helps people lose an average of 25-35% of their total body weight within one to two years. The fact that retatrutide achieved such significant weight loss in just 80 weeks raises questions about its potential as a convenient and effective alternative to traditional surgical interventions.

Retatrutide’s unique mechanism of action, which mimics the hormones GLP-1, GIP, and glucagon, may be key to its impressive weight loss results. This is distinct from other GLP-1 medications like Wegovy and Zepbound, which only mimic GLP-1.

Dr. Susan Spratt, an endocrinologist at Duke Health, praised the trial’s findings, calling them “huge.” However, she noted that side effects such as nausea, constipation, and diarrhea are a concern. Patients taking retatrutide also reported more unusual or uncomfortable skin sensations and urinary tract infections compared to those on placebo.

The convenience of retatrutide is indeed a major selling point for Eli Lilly. Unlike bariatric surgery, which requires significant lifestyle changes and carries its own risks, retatrutide can be taken as a simple weekly injection. However, this convenience may come at a cost: the rate of patients dropping out of the trial was higher than that seen with Zepbound but similar to rates seen with Wegovy.

Retatrutide may also offer hope for people who do not respond to current GLP-1 medications. Dr. Shauna Levy, medical director of the Tulane Weight Loss Center, noted that around 10% of patients do not lose weight on existing GLPs – an issue that may be more common than thought.

The success of retatrutide raises questions about the future of obesity treatment. As the medical community grapples with the growing epidemic of excess weight, new medications like retatrutide offer hope for those struggling to lose weight through diet and exercise alone. However, we must also consider the potential consequences of relying on medication as a primary solution.

Eli Lilly has not yet filed for FDA approval, but it is expected to do so soon. As the regulatory process unfolds, one thing is clear: retatrutide has the potential to be a game-changer in the fight against obesity. But will it live up to its promise? Only time – and rigorous clinical trials – will tell.

The true value of retatrutide lies not just in its impressive weight loss results but in its potential to transform the way we approach obesity treatment. If approved, this new medication could be a beacon of hope for millions struggling with excess weight. But as we welcome this new innovation into the market, let us also acknowledge the complexities and challenges that come with it – and strive for a more nuanced understanding of what true progress in healthcare really means.